Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis
about
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice.Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014Plasma drug activity in patients on treatment for multidrug-resistant tuberculosisUnderstanding pharmacokinetics to improve tuberculosis treatment outcome.Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory.Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania.Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid.Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.Antituberculosis drugs in children.Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis.Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates
P2860
Q24202081-7C493A62-9DA7-451F-9219-682B368D984BQ28543642-DD3F336D-1EE7-487F-AA0B-7CC1C71611F6Q30300207-7C0ACE2C-CCD2-417C-84BF-0DB6FD3BE525Q30411475-7AE5F1E8-57D7-4DC3-AF37-63E07AF9FE67Q30411703-83CC76C2-E5B5-4786-940B-80B87B75ABB2Q30414792-3751CB7A-5955-4564-8755-1A9DBB5A4BBFQ30415943-6852F170-15E5-4923-AD8F-BD67B14B37F7Q35167178-F0BA3AC3-7941-4466-874A-0AE450EF2744Q36075800-368A11D8-983C-42CE-BD85-19B2B07DAFD4Q37434301-63D88FAF-E768-4305-B7B4-22C16645B771Q37544479-D95B0A30-B32C-4B0A-AEDA-62727A70F7B5Q38533435-3D6782A7-0FEA-4DAC-BC5D-D0B49963AC35Q40211670-ACE21C7C-285D-4A2B-84A0-6F9AAEDBFA74Q41105755-8F541696-216D-45EF-AF84-85366185F2B5Q42281128-FC42FE43-02C2-47CA-B507-28286EBC6A27Q42693542-AB51D42C-51F4-4ADB-BAD7-B9A1B163963D
P2860
Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Population pharmacokinetics an ...... ltidrug-resistant tuberculosis
@ast
Population pharmacokinetics an ...... ltidrug-resistant tuberculosis
@en
type
label
Population pharmacokinetics an ...... ltidrug-resistant tuberculosis
@ast
Population pharmacokinetics an ...... ltidrug-resistant tuberculosis
@en
prefLabel
Population pharmacokinetics an ...... ltidrug-resistant tuberculosis
@ast
Population pharmacokinetics an ...... ltidrug-resistant tuberculosis
@en
P2093
P2860
P50
P921
P356
P1476
Population pharmacokinetics an ...... ltidrug-resistant tuberculosis
@en
P2093
Carl M J Kirkpatrick
Emmanuel Chigutsa
Joe Harding
Marc Weiner
Prashini Moodley
Sandra Meredith
William R Mac Kenzie
P2860
P304
P356
10.1128/AAC.00048-12
P407
P577
2012-05-07T00:00:00Z